Trials / Completed
CompletedNCT03033498
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 45 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety, tolerability, and pharmacokinetics of single, ascending doses of ABBV-951 administered as a subcutaneous bolus infusion followed by a continuous subcutaneous infusion in subjects with Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-951 | ABBV-951 administered by subcutaneous infusion. |
Timeline
- Start date
- 2017-05-17
- Primary completion
- 2019-06-08
- Completion
- 2019-06-08
- First posted
- 2017-01-26
- Last updated
- 2024-11-12
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03033498. Inclusion in this directory is not an endorsement.